Procedures and Therapies

Hematopoietic growth factors and chemotherapy in cancer treatment (07/26/2011)
(...) Hematopoietic growth factors have played a significant role in preventing infection in cancer patients by shortening the amount of neutropenia in those receiving chemotherapy. Patients can better tolerate the conventional treatment regimen and could have the ability to tolerate higher doses of chemotherapeutic agents, which might improve therapeutic outcomes. Four hematopoietic growth factors happen to be approved by the FDA, and several other growth factors are being studied in many studies. (...)

Vaccine and gene therapy in various malignancies (07/26/2011)
(...) It's well tolerated due to the low toxicity. The most popular side-effect is really a local reaction in the injection site comprising erythema, pruritus, inflammation, or tenderness. Gene therapy Gene treatments are a method in which new genetic material is inserted right into a patient's cell to fix an inborn genetic error in order to introduce a brand new biologic function towards the cell. (...)

Chemotherapy progress and drug development in cancer treatment (07/26/2011)
(...) Drug development The entire process of translating the brand new knowledge gained in the bench is long and expensive. Drug development begins with buying and screening of chemical substances. Screening is performed on these compounds using animal or human cancer cells grown in vitro, transplanted animal tumors, and human xenografts. (...)

Chemotherapy pretreatment patient and family assessment (07/26/2011)
(...) ... (...)

Intrahepatic chemotherapy in cancer treatment (07/26/2011)
(...) The pump should be manipulated only by qualified personnel, who should stick to the manufacturer's instructions regarding proper use. Flow rates vary from 1 to 2 mL/day and therefore are predetermined by the manufacturer. Flow rates increase at high altitudes, with fever, with hypertension. (...)

Managing cardiotoxicity during chemotherapy treatment (07/26/2011)
(...) The utilization of the new cardiac protectant, dexrazoxane, in doxorubicin therapy for advanced breast cancer may help diminish the incidence of cardiac toxicity. In severe cases, the chemotherapeutic agents should be discontinued and supportive measures provided. onitor the patient's cardiac function by obtaining cardiac enzymes, multigated radionuclide angiography, and electrocardiograms before and throughout treatment. (...)

Alopecia is the most common effect of chemotherapy (07/26/2011)
(...) Whenever a hair follicle enters the anagen phase, the upward growth of the new hair causes the dormant hair to shed. Due to this growth and dormancy cycle, an ordinary person usually sheds 100 scalp hairs daily. The active hair bulbs duplicate every 12 to Twenty four hours, resulting in a regular growth of the hair shaft of 0. (...)

How chemotherapy affects nails (07/26/2011)
(...) Management and patient education Measure the patient's nails before chemotherapy administration. Advise the individual of potential changes in the nails and get her or him to report any changes. These usually occur 5 to 10 weeks after chemotherapy. (...)

Connection between chemotherapy and anorexia (07/26/2011)
(...) Teach the individual to weigh themselves once per week and also to report an appetite suppressant of 3 lb or more each week. Monitor protein and albumin levels. Analyze dietary intake and instruct the individual to maintain a 3-day journal of intake. (...)

Mucositis management and patient education (07/26/2011)
(...) Rinse the mouth with warm saline or with those who are rinses. Peroxide mouthwash isn't recommended since it disturbs the standard flora of the mouth and results in overgrowth of fissures and white papillae of the tongue, resulting in candidiasis. Wear dentures only when necessary. (...)

Diarrhea during chemotherapy and its complications (07/26/2011)
(...) Assess bowel function and elimination pattern. Monitor weight, intake and output, and electrolytes. Administer IV fluids or electrolytes as ordered. (...)

Treating anemia as a result of intense chemotherapy (07/26/2011)
(...) Evaluate dietary intake. Let the patient to consume foods that are rich in iron, vitamins, and minerals. Suggest nutritional or iron and nutritional vitamin supplements if required. (...)

Thrombocytopenia management during chemotherapy (07/26/2011)
(...) Use stool softeners to prevent straining, which could cause rectal tearing and bleeding. Avoid performing the Valsalva maneuver when moving or defecating. Consume a high-fiber diet and drink lots of fluids to prevent constipation. (...)

Nephrotoxicity can be a serious side effect of chemotherapy (07/26/2011)
(...) If oral those who are or citrovorum rescue is ordered, make sure the individual knows the significance of taking these medications as scheduled. Let the patient to drink enough fluids before and after treatment. Give uroprotectants for example mesna or allopurinol to improve the crystals excretion, if ordered. (...)

Pulmonary toxicity as a result of chemotherapy (07/26/2011)
(...) The pulmonary damage brought on by bleomycin is dose-related; patients who get a cumulative dose in excess of 450 units show a greater incidence of toxicity compared to those who get a lower cumulative dose. In busulfan therapy, the busulfan lung syndrome can happen and it has an undesirable prognosis. Dyspnea may be the cardinal characteristic of chemotherapy-induced pulmonary toxicity. (...)

Home care for cancer patients under chemotherapy (07/26/2011)
(...) Home care allows the individual active participation in and more treatments for the treatment regimen. There's also a wide perception in the lay public that hospitals aren't pleasant and safe places, especially in this current era of downsizing. Visiting any adverse health care facility causes fatigue, and patients feel much more comfortable in their houses underneath the watchful eye of the mate. (...)

Chemotherapy and how it affects cells (07/25/2011)
(...) DNA is a vital nucleic acid made up of deoxyribose, a phosphate, and four nitrogenous bases: adenine, guanine, cytosine, and thymine. Adenine and guanine would be the purines, and cytosine and thymine would be the pyrimidines. Chemical reactions occur between your two purines as well as between your two pyrimidines, resulting in the development of the double-stranded DNA helix, which can serve as the genetic template of the cell. (...)

Short classification of some chemotherapeutic agents (07/25/2011)
(...) The amount of cells in cycle is called the development fraction. Cell cycle-specific drugs therefore lessen the growth fraction of the tumor. Antimetabolites Antimetabolites are synthetically formulated to imitate the naturally produced metabolites, purines, pyrimidines, or folates required for the synthesis of nucleic acids and DNA. (...)

Alkylating agents used in chemotherapy to fight cancer cells (07/25/2011)
(...) These drugs, that are hormonal or hormone-like agents, inhibit tumor proliferation by blocking or antagonizing the naturally sourced substance that stimulates tumor growth... (...)

Chemotherapy and Biologic Response Modifiers in cancer treatment (07/25/2011)
(...) The nation's Cancer Institute's Division of Cancer Treatment Subcommittee on Biological Response Modifiers has defined BRMs as agents or approaches that affect the relationship between host and tumor by changing the host's immune reaction to tumor cells, which ends in a therapeutic effect. BRMs include mAbs, cytokines, along with other biologic agents for example tumor necrosis factor. Many BRMs they are under investigation in many studies. (...)

Immunotoxin therapy and chemotherapy in cancer treatment (07/25/2011)
(...) The recommended dose is 9 or 18 mg/kg/day adminis-tered intravenously over Fifteen minutes for 5 consecutive days every A 3 week period. Ontak is generally well tolerated; however, negative effects include chills, fever, infection, pain, headache, flulike syndrome, dizziness, heart problems, hypotension, tachycardia, nausea, vomiting, diarrhea, and hypoalbuminemia. Conjugation of mAbs to radioisotopes has both diagnostic and therapeutic applications. (...)